13 May 2009

Preliminary Results for the year ended 31 December 2008

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce its preliminary results for the year ended 31 December 2008.

Highlights

• Substantial progress across the Company with receipt of positive regulatory opinion relating to the pharmaceutical aspects of CSD500, which will be the first commercial product
• TPR100 - Positive results from phase I study with commercial negotiations ongoing
• PET500 - Positive results from phase I study
• RAD100 - New product for local anaesthesia prior to injections which has shown impressive results in early clinical work
• Net loss of £1.93 million (2007: net loss of £2.25 million)
• Cash of £0.78 million at 31 December 2008 with a further £1.00 million equity funding raised in March 2009

James Barder, Futura's Chief Executive, said: "We are making good progress across our product portfolio whilst being very mindful of our resources and product priorities. We remain firmly on course to becoming a revenue generating business with a recurring royalty income stream from CSD500 and share our commercial partner's belief that CSD500 is destined to become a highly successful product."

The full results are available to download in PDF format.

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

© and Database Right: Futura Medical plc 2004 - 2012. All rights reserved.

Site map | Contact us | By using the website, you are deemed to have accepted the terms of the disclaimer.